This study aimed to assess the efficacy of first‐line BRAF/MEKi, Anti‐PD‐1, and PD‐1/CTLA‐4 in Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting. The gene discussed is BRAF; the disease is melanoma.